It's reassuring to hear the CEO confirm that boys who have...

It's reassuring to hear the CEO confirm that boys who have completed the first 6 months of trial, continuing on the program with either 25mg or 50mg dose @Uboy

Thanks Uboy,
Its also reassuring that there are no dropouts from the trial. Conversion to the open label treatment period, no drop outs are encouraging signs. The executives from the due diligence teams are reading the same tea leaves. My sense is that there is a short list and one looks like a really good fit. Maybe someone who sees the opportunity to move into the Duchenne space rather than a current player.

The highest price with the largest upfront and biggest milestones is not always the best outcome. Commitment and ability to expedite to market are even more important. Its the latter that matters.

I recommend that everyone take the opportunity to make it to a Shareholder Open House if and when it comes to your city.